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Abstract
Objective
To evaluate the impact of gentamicin exposure on sensorineural hearing loss (SNHL) in
very low birth weight (VLBW) infants.
Methods
Exposure to gentamicin was determined in infants born between 1993 and 2010 at a gesta-
tional age < 32 weeks and/or with a birthweight < 1500 g, who presented with SNHL during
the first 5 years of life. For each case, we selected two controls matched for gender, gesta-
tional age, birthweight, and year of birth.
Results
We identified 25 infants affected by SNHL, leading to an incidence of SNHL of 1.58% in
our population of VLBW infants. The proportion of infants treated with gentamicin was
76% in the study group and 70% in controls (p = 0.78). The total cumulated dose of genta-
micin administered did not differ between the study group (median 10.2 mg/kg, Q1-Q3
1.6–13.2) and the control group (median 7.9 mg/kg, Q1-Q3 0–12.8, p = 0.47). The median
duration of gentamicin treatment was 3 days both in the study group and the control
group (p = 0.58). Maximum predicted trough serum levels of gentamicin, cumulative
area under the curve and gentamicin clearance were not different between cases and
controls.
Conclusion
The impact of gentamicin on SNHL can be minimized with treatments of short duration,
monitoring of blood levels and dose adjustment.
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Introduction
Preterm newborns are at risk of neurodevelopmental impairments such as cerebral palsy, cog-
nitive, behavioral and sensory disabilities including hearing loss [1–3]. The incidence of senso-
rineural hearing loss (SNHL) is in the wide range of 0.4–5% among very low birthweight
(VLBW) infants [2–8]. Therefore, screening for hearing loss is recommended during the neo-
natal period and during neurodevelopmental follow-up. A number of risk factors for SNHL
have been described, including low gestational age and birthweight, intrauterine and postnatal
infections, neonatal asphyxia, requirement for prolonged oxygen therapy and respiratory sup-
port, hyperbilirubinemia requiring exchange transfusion, hyponatremia, surgery during the
neonatal period, congenital malformations, family history of hearing impairment, genetic
abnormalities, and exposure to ototoxic medications such as diuretics and antibiotics [4, 9–23].
A large proportion of premature newborns are exposed to intravenous antibiotics. Indeed,
invasive bacterial infection affects up to 25% of VLBW infants [24, 25]. The manifestations of
infection are often unspecific and progression can be very rapid with a high risk of morbidity
and mortality. Therefore, empirical antibiotic therapy is started at birth in the presence of risk
factors for infection, and/or at the slightest suspicion of infection during the neonatal period.
Gentamicin is one of the most commonly used antibiotics for empirical treatment of neonatal
sepsis [26, 27]. Animal experiments and clinical studies on adults and children indicate that
gentamicin can cause damage to the inner ear cells, resulting in irreversible SNHL. Gentami-
cin-related ototoxicity depends on the total dose administered, the duration of treatment, as
well as serum concentrations [28]. Therapeutic drug monitoring (TDM) has thus been recom-
mended during gentamicin treatment in order to achieve efficient serum concentrations of the
drug and to minimize the risk of ototoxicity.
The impact of gentamicin treatment on the development of SNHL is controversial in new-
borns [29]. Early studies have found an association between aminoglycoside treatment and
SNHL in newborn infants [12, 30]. A case-control study conducted at our institution between
1987 and 1991 identified the number of days of aminoglycoside treatment and the total cumu-
lated dose of aminoglycosides as a risk factor for SNHL in premature infants [15]. However,
since the early 1990s, a number of clinical studies have suggested that gentamicin administered
in controlled therapeutic doses is not associated with ototoxicity in newborn infants [18, 21,
31–36]. Yet, controversies persist [17, 20, 23, 29, 37], and the dose, duration of treatment and
circulating concentrations of gentamicin associated with the development of SNHL in VLBW
infants have not been clearly determined.
Given the changes in the care of preterm neonates over the last twenty years, we decided to
reassess the relationship between exposure to gentamicin and development of SNHL in prema-
ture newborns. We conducted a retrospective case-control study to determine the impact of
gentamicin exposure and other potential risk factors on the development of SNHL in VLBW
infants born between 1993 and 2010, and hospitalized at the University Hospital of Lausanne
during the neonatal period.
Patients and Methods
Study design
This case-control study was approved by the local Human Research Ethics Committee (Com-
mission cantonale d’éthique de la recherche sur l’être humain). Informed consent was not
required due to the retrospective nature of the study. Patient information was anonymized and
de-identified prior to analysis. Infants were included in the study group if they met all the fol-
lowing criteria: 1) date of birth between January 1, 1993 and December 31, 2010; 2) gestational
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age at birth< 32 weeks and/or birthweight< 1500 g; 3) hospitalization at the University Hos-
pital of Lausanne during the neonatal period; 4) SNHL diagnosed during the first 5 years of
life. For each case, we identified two controls matched for gender, gestational age, birthweight
and year of birth.
Audiologic assessment
Patients were identified through the database of the neonatal follow-up clinic of the University
Hospital of Lausanne and the patient records of the pediatric otorhinolaryngologist of our
institution. Testing for hearing impairment was performed before discharge in all infants
born< 32 weeks of gestation and/or with a birthweight< 1500 g by a full diagnostic auditory
brainstem response (ABR) until 2007, and by otoacoustic emissions from then on [38, 39]. Full
diagnostic ABR testing was still performed after 2007 in cases of asphyxia, hyperbilirubinemia
requiring exchange transfusion, and in the presence of major brain lesions or malformations
associated with hearing loss. Patients with abnormal tests were referred to the pediatric otorhi-
nolaryngologist for a comprehensive audiological evaluation including a full diagnostic ABR.
All patients were assessed again at an age of 18 months, 3.5 years and 5 years by the Stycar
hearing test or the whispered voice test [40]. Children with abnormal Stycar or whispered voice
tests were referred to the pediatric otorhinolaryngologist for a comprehensive audiological
evaluation by usual conditioned reaction audiometry or play audiometry, and a full diagnostic
ABR.
Gentamicin and aminoglycosides dosing regimens and therapeutic drug
monitoring
Infants treated with gentamicin received an initial dose of 2.5–3 mg/kg. TDM was performed
by measuring peak and trough gentamicin blood levels 1 and 12 hours after administration of
the initial dose. Recommendations for gentamicin dose and interval were provided by clinical
pharmacologists, based on a two-points linear regression [41], in order to achieve peak and
trough gentamicin levels of 6–8 and 1–1.5 mg/L. Gentamicin peak and trough levels were con-
trolled on the 4th dose in infants treated for> 5 days or in the presence of renal failure and/or
concomitant treatment with indomethacin, ibuprofen or furosemide. Infants treated with ami-
kacin and tobramycin received an initial dose of 7.5–10 mg/kg and 2.5 mg/kg, and TDM was
performed similarly to gentamicin.
Risk factors and data collection
The primary causal attribute studied consisted in several descriptors of gentamicin treatment.
The cumulated dose of gentamicin (mg/kg) was calculated by dividing the total dose adminis-
tered to the patient by the patient’s body weight during gentamicin treatment. The duration of
gentamicin treatment, as well as maximum measured peak and 12-hour plasma concentrations
were recorded. Treatments with other aminoglycosides were also recorded. Gentamicin indi-
vidual pharmacokinetic (PK) parameters were retrieved by maximum a posteriori Bayesian
estimation [42], and were used to calculate the maximum predicted trough concentration dur-
ing gentamicin treatment, the total cumulative area under the gentamicin concentration curve
(AUC), and the systemic clearance of gentamicin.
Secondary study attributes included general clinical characteristics and conditions and
other treatments identified as potential risk factors for SNHL in newborn infants [4, 9–15, 17–
21]. Clinical data were retrieved from the database of the neonatal follow-up clinic and by med-
ical chart review. We recorded data on medications, respiratory support and lung disease,
hemodynamics, blood chemistry, infections, gastrointestinal complications, congenital
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malformations, chromosomal abnormalities and neurodevelopmental outcomes. The following
neurodevelopmental impairments were recorded: 1) cognitive disability, defined by an intellec-
tual quotient 2 standard deviations below the mean for the population; 2) cerebral palsy; 3)
visual impairment not corrected by visual aids; 4) autistic spectrum disorder, defined as a
behavioral disorder affecting communication and social skills.
Statistical analyses
Baseline clinical characteristics were described by showing the median and the first and third
quartiles (Q1–Q3) for continuous variables, and numbers and percentages for categorical vari-
ables. Group comparisons were performed using Mann–Whitney and Fisher’s Exact tests.
Associations between hypothesized risk factors and SNHL were evaluated using logistic
regression analysis. Results were contrasted between the study group and the control group.
Odd ratios and corresponding p-values were first assessed by univariate analyses. Associations
that were evidently constructed were not tested (e.g. matching criteria). Then, candidate risk
factors other than aminoglycosides that revealed a trend for an individual association with
SNHL (p< 0.2) were entered into a stepwise multivariate analysis and backward eliminated
until obtaining a parsimonious model that retained factors at least loosely associated with
SNHL (p< 0.1). Eventually, the descriptors of gentamicin exposure were forced sequentially
into the model to evaluate their own contribution. Statistical analyses were performed using
the STATA software (version 13.1, StataCorp, Texas, USA).
Results
A total of 1888 VLBW infants born between January 1, 1993 and December 31, 2010 were hos-
pitalized at our institution. Their median gestational age was 29 5/7 weeks (Q1-Q3 27 4/7-31 0/
7) and their median birthweight was 1195 g (Q1-Q3 910–1420). Two hundred and twenty six
infants died during the neonatal period (12%) and 80 were lost to follow-up. Thus, 95% of the
surviving patients were seen at the neonatal follow up clinic at least once, and 75% were evalu-
ated up to 3 ½—6 years of age.
Among this population of 1582 VLBW infants, we identified a study group of 25 patients
who developed SNHL during the first 5 years of life, leading to an incidence of SNHL of 1.58%.
Demographic and perinatal characteristics were similar between cases and controls (Table 1).
In the study group, one patient presented a congenital infection with cytomegalovirus, and one
patient was affected by 18q- syndrome, a chromosomal abnormality associated with hearing
impairment. No patient had an anomaly of ear or face, or a family history of hearing loss.
Table 1. Demographic and perinatal characteristics.
study group (n = 25) control group (n = 50) p value
Female gender, n (%) 13 (52) 26 (52) 1.00
Gestational age, weeks [median (Q1-Q3)] 28 (26–31) 28 (26–31) 0.70
Birthweight, grams [median (Q1-Q3)] 780 (690–1100) 835 (660–1090) 0.91
Umbilical artery pH [median (Q1-Q3)] 7.27 (7.23–7.33) 7.27 (7.21–7.32) 0.93
Umbilical vein pH [median (Q1-Q3)] 7.31 (7.28–7.37) 7.34 (7.29–7.37) 0.53
1 min Apgar score [median (Q1-Q3)] 6 (2–7) 4 (3–6) 0.70
5 min Apgar score [median (Q1-Q3)] 8 (6–8) 7 (6–9) 0.83
10 min Apgar score [median (Q1-Q3)] 9 (7–9) 8 (7–9) 0.99
Cesarean section, n (%) 21 (84) 42 (84) 1.00
Antenatal steroids, n (%) 19 (76) 39 (78) 1.00
Preeclampsia, n (%) 5 (20) 7 (14) 0.52
doi:10.1371/journal.pone.0158806.t001
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Audiologic and neurodevelopmental outcomes of the study group are reported in Table 2.
Twenty two patients had an abnormal ABR test during the neonatal period, 2 patients were
diagnosed at 18 months, and 1 patient was diagnosed at 5 years. All patients with hearing loss
were followed by an otorhinolaryngologist, and were treated with hearing aids, speech and lan-
guage therapy. Besides SNHL, other severe neurodevelopmental impairments occurred in 11/
25 (44%) of the patients from the study group, and 6/50 (12%) of the patients from the control
group (p = 0.002).
The proportion of infants treated with gentamicin was 76% in cases vs 70% in controls
(p = 0.78). The median duration of gentamicin treatment was 3 days (Q1-Q3 1–5) in cases and
3 days in controls (Q1-Q3 0–5, p = 0.58). The total cumulated dose of gentamicin did not differ
between cases (median 10.2 mg/kg, Q1-Q3 1.6–13.2) and controls (median 7.9 mg/kg, Q1-Q3
0–12.8, p = 0.47, Table 3). Among infants treated with gentamicin, maximum observed
peak and 12 h levels were similar between cases and controls. The univariate analysis of the
derived gentamicin PK parameters did not show any significant difference between the two
groups for cumulative AUC (p = 0.79), clearance (p = 0.78), and maximum predicted trough
Table 2. Audiologic status and neurodevelopmental outcome in the study group.
Patient No. GAa (weeks) BWb (grams) ABRc thresholdleft ear (dB) ABR threshold right ear (dB) Other severe impairments
1 28 5/7 1000 90 40 -
2 29 730 60 50 Cognitive disabilityd
3 28 4/7 1160 70 95 -
4 28 1/7 550 60 60 Cognitive disability, cerebral palsy
5 25 3/7 650 50 50 -
6 25 4/7 600 60 70 -
7 29 3/7 1000 70 70 -
8 31 1/7 780 100 30 -
9 25 5/7 580 0 50 Cognitive disability, cerebral palsy
10 25 2/7 770 70 60 Cognitive disability, visual impairmente
11 26 780 80 60 Cognitive disability, visual impairment
12 31 2030 40 40 Cognitive disability, cerebral palsy
13 24 2/7 690 0 60 -
14 26 6/7 610 70 40 -
15 32 5/7 1370 90 90 Cerebral palsy
16 27 5/7 900 60 60 -
17 26 6/7 910 90 90 -
18 31 4/7 1670 20 30 -
19 30 6/7 1600 40 70 Cognitive disability, cerebral palsy
20 32 1/7 860 50 40 Cognitive disability
21 31 1200 80 70 Cognitive disability, cerebral palsy
22 29 5/7 1100 60 60 -
23 24 5/7 720 90 90 Cognitive disability, cerebral palsy
24 25 4/7 700 60 90 -
25 27 1/7 475 50 90 -
aGA: gestational age
bBW: birthweight
cABR: auditory brainsterm response
dDeﬁned as an intellectual quotient 2 SD below the mean
eNot corrected by visual aids
doi:10.1371/journal.pone.0158806.t002
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concentrations (p = 0.76). The mean cumulative AUC of gentamicin was 404 ± 217 mg/L/h in
cases and 391 ± 162 mg/L/h in controls, with a 95% confidence interval (CI) for the difference
between means of -84 to 109 [43].
Four patients were treated with amikacin in the study group and 9 in the control group; one
patient was treated with tobramycin in the study group, and one patient received netilmicin in the
control group. The proportion of infants treated with any aminoglycoside was 80% among cases,
and 78% among controls (p = 1.00). The total cumulated dose of aminoglycosides, the total dura-
tion of aminoglycoside treatment, and the maximum observed peak and 12 h levels of aminoglyco-
sides were similar between cases and controls. The proportion of infants treated with furosemide,
neuromuscular blocking agents and/or vancomycin was not different between cases and controls.
There was a higher incidence of pneumothorax in the study group than in the control group
(20% vs 4%, p = 0.04, Table 4). Compared to controls, infants from the study group had a lon-
ger duration of mechanical ventilation and oxygen treatment, more frequently required cate-
cholamine treatment for hypotension and as well as non-steroidal anti-inflammatory agents
for patent ductus arteriosus. However, these differences did not reach statistical significance.
The multivariate analysis included risk factors unrelated to aminoglycosides with a p-
value< 0.2. It produced a model which only retained pneumothorax and sepsis as factors over-
represented in patients with SNHL with odds ratios of 6.9 (95% CI 1.2–39.1, p = 0.03) and 2.8
(95% CI 0.9–8.9, p = 0.09) respectively. When parameters of exposure to gentamicin were seri-
ally entered in this reduced model one by one, none of them was significant (p> 0.5 for all).
Altogether, the introduction of gentamicin treatment descriptors did not improve the model
(p = 0.4, likelihood ratio test).
Discussion
The impact of gentamicin on SNHL, once considered as major, is currently controversial in
newborns. Here, we present a detailed analysis of gentamicin exposure in preterm infants that
developed SNHL, and compare it with well-matched controls. Our results support the idea that
gentamicin administration in therapeutically controlled doses is not associated with SNHL in
VLBW infants.
Table 3. Gentamicin and other potentially ototoxic medications.
study group (n = 25) control group (n = 50) p value
Gentamicin, n (%) 19 (76) 35 (70) 0.78
Duration of gentamicin treatment, days [median (Q1-Q3)] 3 (1–5) 3 (0–5) 0.58
Total cumulated dose of gentamicin, mg/kg [median (Q1-Q3)] 10.2 (1.6–13.2) 7.9 (0–12.8) 0.47
Maximum observed peak concentration of gentamicin, mg/L [median (Q1-Q3)] 5.7 (4.3–9.1) 5.6 (4.3–7.8) 0.67
Maximum observed 12 h concentration of gentamicin, mg/L [median (Q1-Q3)] 2.0 (1.7–2.4) 2.3 (1.8–2.6) 0.43
Maximum predicted trough concentration of gentamicin, mg/L [median (Q1-Q3)] 1.5 (1.3–1.8) 1.6 (1.3–1.8) 0.76
Cumulative AUC of gentamicin, mg/L/h [median (Q1-Q3)] 387 (223–539) 373 (288–478) 0.79
Clearance of gentamicin L/h/kg [median (Q1-Q3)] 0.037 (0.031–0.042) 0.036 (0.029–0.042) 0.78
Aminoglycoside, n (%) 20 (80) 39 (78) 1.00
Duration of aminoglycoside treatment, days [median (Q1-Q3)] 4 (2–7) 4 (2–7) 0.90
Median total cumulated dose of aminoglycosides, mg/kg (Q1-Q3) 17.5 (8.5–38.12) 12.7 (5.0–21.1) 0.15
Maximum observed peak concentration of aminoglycosides, mg/L [median (Q1-Q3)] 7.0 (5.0–11.6) 6.6 (4.4–8.8) 0.44
Maximum observed 12 h concentration of aminoglycosides, mg/L [median (Q1-Q3)] 2.0 (1.7–3.4) 2.4 (1.8–2.7) 0.41
Vancomycin treatment, n (%) 16 (64) 25 (50) 0.33
Furosemide treatment, n (%) 9 (36) 10 (20) 0.16
Neuromuscular blocking agents, n (%) 5 (20) 6 (12) 0.49
doi:10.1371/journal.pone.0158806.t003
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The reported incidence of SNHL in VLBW infants varies widely between 0.4% and 5% in
different studies [2–8]. At our institution, we found an incidence of SNHL of 1.58% in VLBW
infants born between 1993 and 2010. Most of the patients were diagnosed during the neonatal
period. In a study conducted in our neonatal intensive care unit in infants born< 35 weeks of
gestation between 1987 and 1991, Borradori et al. found an incidence of SNHL of 1.46% [15].
The patients described by Borradori et al. were more mature (median gestational age 30 4/7)
than the patients described in the present study (median gestational age 28 weeks). This differ-
ence is likely to reflect improvements in obstetric and neonatal intensive care during the past
decades, resulting in the survival of more immature newborns. It is also noticeable that the
exposure to gentamicin or other aminoglycosides reported by Borradori et al. was higher to the
levels recorded in the present study, with average aminoglycoside treatment duration of 25
days, average cumulative gentamicin dose of 21.5 mg/kg, average trough concentrations of 3.0
mg/L, and frequent treatment rotation with tobramycin. This level of exposure, not unusual in
the 1980s, was likely to be associated with ototoxic consequences.
In the present study, the majority of VLBW infants who developed SNHL were exposed to
gentamicin, however at clearly lower doses, durations and concentrations than in the 1980s.
Actually, there was no difference between cases and controls in the proportion of infants
exposed to gentamicin, in the duration of gentamicin treatment, in the total cumulated dose, in
maximum observed peak and 12 h gentamicin levels, and in individual estimates of gentamicin
PK parameters (cumulative AUC, gentamicin clearance, maximum predicted trough level).
Overall, the rate of morbidities tended to be higher in patients affected by SNHL compared
to controls. Pneumothorax is reported to occur in 2–10% of VLBW infants, depending on clin-
ical practices for respiratory support [44, 45]. In the present study, the incidence of pneumo-
thorax was 20% in the study group and 4% in controls, confirming the relationship between
pneumothorax and SNHL that was previously identified at our institution [15]. Hypoxemia is
a risk factor for hearing loss [21, 23]. We speculate that episodes of hypoxemia associated with
pneumothoraces could have contributed to the development of SNHL. In contrast to previous
Table 4. General clinical data.
study group (n = 25) control group (n = 50) p value
Invasive ventilation, n (%) 19 (76) 35 (70) 0.78
Duration of invasive ventilation, hours [median (Q1-Q3)] 144 (23–240) 75 (0–288) 0.47
Non-invasive ventilation, n (%) 21 (84) 45 (90) 0.47
Duration of non-invasive ventilation, hours [median (Q1-Q3)] 672 (288–1392) 696 (48–1240) 0.48
Duration of oxygen supplementation, hours [median (Q1-Q3)] 1008 (48–1704) 480 (24–1416) 0.21
Bronchopulmonary dysplasiaa, n (%) 15 (60) 22 (44) 0.23
Pneumothorax, n (%) 5 (20) 2 (4) 0.04
Medically treated patent ductus arteriosus, n (%) 14 (56) 19 (38) 0.15
Surgically treated patent ductus arteriosus, n (%) 5 (20) 6 (12) 0.48
Hypotension treated with catecholamines, n (%) 7 (28) 8 (16) 0.23
Hyponatremia < 130 mmol/L, n (%) 5 (20) 12 (24) 0.78
Blood culture-proven sepsis, n (%) 8 (32) 8 (16) 0.14
Necrotizing enterocolitisb, n (%) 4 (17) 6 (12) 0.73
Gastrointestinal surgery, n (%) 1 (4) 1 (2) 1.00
Cerebral hemorrhage grade III or IV, n (%) 2 (8) 1 (2) 0.26
Periventricular leukomalacia, n (%) 3 (12) 2 (4) 0.33
aDeﬁned as oxygen supplementation for > 28 days
bBell stage 2
doi:10.1371/journal.pone.0158806.t004
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studies, in our univariate analyses, we did not find associations between SNHL and several
other known risk factors such as medication, respiratory and cardiovascular support, and sur-
gical complications. However, there was a trend towards a higher use of furosemide and neuro-
muscular blocking agents, a higher rate of blood culture-proven sepsis, a longer duration of
mechanical ventilation and oxygen therapy, and a higher incidence of patent ductus arteriosus
in infants who developed SNHL. The proportion of infants affected by other severe neurodeve-
lopmental disabilities in addition to their hearing impairment was higher in the study group
compared to controls. This suggests that SNHL is multifactorial in origin, and part of a global
neurodevelopmental impairment following complications of preterm birth.
The strength of the present study is the large number of VLBW infants included, along with
a high rate of follow up, and a detailed analysis of gentamicin exposure. A limitation is the ret-
rospective nature of the study. The relatively low number of patients affected by SNHL in our
study is reassuring. On the other hand, this low number combined with a high variance in
exposure to gentamicin lead to 95% CIs around the observed difference in gentamicin exposure
that are consistent with as much as 25% higher exposure to gentamicin in infants who devel-
oped SNHL. Previous studies reporting on the absence of ototoxicity of gentamicin in new-
borns also suffer from methodological limitations including a small size, incomplete
information on gentamicin exposure and absence of long term audiologic assessment [21, 33–
36, 46, 47]. Hearing impairment may have resulted from the combined effect of prematurity,
low birthweight, gentamicin treatment and other ototoxic medications such as furosemide and
vancomycin, and genetic factors. Indeed, genetic variants can predispose to hearing loss. Mito-
chondrial DNAmutations have been linked to sensitivity to aminoglycosides and have also
been associated with hearing loss in the absence of exposure to aminoglycosides [48]. Screening
for genetic variants associated with hearing loss could identify patients at risk, but the opportu-
nity for prevention may be limited as gentamicin is often prescribed on the first day of life for
suspected early-onset sepsis [37, 49, 50]. We did not determine the prevalence of mutations
predisposing for aminoglycoside toxicity. Vestibular toxicity was not investigated.
In conclusion, SNHL remains a serious complication of prematurity. Gentamicin is a potentially
ototoxic medication. However, gentamicin-related ototoxicity can be minimized with relatively short
treatments, close monitoring of blood levels, dosage adjustment, and ideally future genetic testing. A
large prospective study with long term audiologic follow up is required to confirm our findings.
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